10. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated 
gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. 
Cancer Res 1990; 50:7820-7825. 
1 1 . Watanabe N, Vande Woude GF, Dcawa Y, Sagata N. Specific proteolysis of the c-mos proto-oncogene 
product by calpain on fertilization of Xenopus eggs [see comments]. Nature 1989; 342:505-51 1. 
12. Watanabe T, Endo A. Species and strain differences in teratogenic effects of biotin deficiency in rodents [see 
comments]. J Nutr 1989; 119:255-261. 
13. Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the 
cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor, correlation with antigen 
presentation capability. J Exp Med 1992; 175:1423-1431. 
14. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor cells secreting 
gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility 
complex expression. Cancer Res 1991; 51:1185-1189. 
15. Pandolfi F, Boyle LA, Trentin L, Kumick JT, Isselbacher KJ, Gattoni Celli S. Expression of HLA-A2 
antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991; 51:3164-3170. 
16. Ogasawara M, Rosenberg SA. Enhanced expression of HLA molecules and stimulation of autologous 
human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon 
genes. Cancer Res 1993; 53:3561-3568. 
17. Marozzi A, Meneveri R, Bunone G, De Santis C, Lopalco L, Beretta A, Agresti A, Siccardi AG, Della 
Valle G, Ginelli E. Expression of beta 2m-free HLA class I heavy chains in neuroblastoma cell lines. Scand 
J Immunol 1993; 37:661-667. 
18. Lampson LA, Fisher CA. Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be 
modulated by interferon. Proc Natl Acad Sci U S A 1984; 81:6476-6480. 
19. Lampson L/^ George DL. Interferon-mediated induction of class I MHC products in human neuronal cell 
lines: analysis of HLA and beta 2-m RNA, and HLA-A and HLA-B proteins and polymorphic specificities. 
J Interferon Res 1986; 6:257-265. 
20. Naganuma H, Kiessling R, Patarroyo M, Hansson M, Handgretinger R, Groenberg A. Increased 
susceptibility of IFN-gamma-treat^ neuroblastoma cells to lysis by lymphokine-activated killer cells: 
participation of ICAM-1 induction on target cells. Int J Cancer 1991; 47:527-532. 
2 1 . Shimizu H, Fujimoto T. Susceptibility of NB-I neuroblastoma cells to tumoricidal activity of monocytes 
activated by gamma-interferon. Jpn J Cancer Res 1990; 81:1021-1025. 
22. Sugio K, Nakagawara A, Sasazuld T. Association of expression between N-myc gene and major 
histocompatibility complex class I gene in surgically resected human neuroblastoma. Cancer 1991; 
67:1384-1388. 
23. Versteeg R, vander Minne C, Plomp A, Sijts A, van Leeuwen A, Schrier P. N-myc expression switched off 
and class I human leukocyte antigen exjH-ession switched on after somatic cell fusion of neuroblastoma 
cells. Mol Cell Biol 1990; 10:5416-5423. 
24. Cooper MJ, Hutchins GM, Mennie RJ, Israel MA. Beta 2-microglobulin expression in human embryonal 
neuroblastoma reflects its developmental regulation. Cancer Res 1990; 50:3694-3700. 
25. Lenardo M, Rustgi AK, SchieveUa AR, Bernards R. Suppression of MHC class I gene expression by 
N-myc through enhancer inactivation. EMBO J 1989; 8:3351-3355. 
26. Digel W, Zahn G, Heinzel G, Pwzsolt F. Pharmacokinetics and biological activity in subcutaneous 
long-term administration of recombinant interferon-gamma in cancer patients. Cancer Immunol Immunother 
1991; 34:169-174. 
Recombinant DNA Research, Volume 19 
